Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States A Retrospective Cohort Study

被引:23
|
作者
Mehta, Hemalkumar B. [1 ]
An, Huijun [1 ]
Andersen, Kathleen M. [1 ]
Mansour, Omar
Madhira, Vithal [2 ]
Rashidi, Emaan S. [1 ]
Bates, Benjamin [3 ]
Setoguchi, Soko [3 ]
Joseph, Corey [1 ]
Kocis, Paul T. [4 ]
Moffitt, Richard [5 ]
Bennett, Tellen D. [6 ]
Chute, Christopher G. [7 ]
Garibaldi, Brian T. [8 ]
Alexander, G. Caleb [1 ,9 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] Palila Software, Reno, NV USA
[3] Rutgers Ctr Pharmacoepidemiol & Treatment Sci, New Brunswick, NJ USA
[4] Penn State Hlth Milton S Hershey Med Ctr, Hershey, PA USA
[5] SUNY Stony Brook, Stony Brook, NY USA
[6] Univ Colorado, Sch Med, Aurora, CO USA
[7] Johns Hopkins Univ, Schools Med Publ Hlth & Nursing, Baltimore, MD USA
[8] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[9] Johns Hopkins Sch Med, Baltimore, MD USA
关键词
GEOGRAPHIC-VARIATION; CARE;
D O I
10.7326/M21-0857
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Relatively little is known about the use patterns of potential pharmacologic treatments of COVID-19 in the United States. Objective: To use the National COVID Cohort Collaborative (N3C), a large, multicenter, longitudinal cohort, to characterize the use of hydroxychloroquine, remdesivir, and dexamethasone, overall as well as across individuals, health systems, and time. Design: Retrospective cohort study. Setting: 43 health systems in the United States. Participants: 137 870 adults hospitalized with COVID-19 between 1 February 2020 and 28 February 2021. Measurements: Inpatient use of hydroxychloroquine, remdesivir, or dexamethasone. Results: Among 137 870 persons hospitalized with confirmed or suspected COVID-19, 8754 (6.3%) received hydroxychloroquine, 29 272 (21.2%) remdesivir, and 53 909 (39.1%) dexamethasone during the study period. Since the release of results from the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial in mid-June, approximately 78% to 84% of people who have had invasive mechanical ventilation have received dexamethasone or other glucocorticoids. The use of hydroxychloroquine increased during March 2020, peaking at 42%, and started declining by April 2020. By contrast, remdesivir and dexamethasone use gradually increased over the study period. Dexamethasone and remdesivir use varied substantially across health centers (intraclass correlation coefficient, 14.2% for dexamethasone and 84.6% for remdesivir). Limitation: Because most N3C data contributors are academic medical centers, findings may not reflect the experience of community hospitals. Conclusion: Dexamethasone, an evidence-based treatment of COVID-19, may be underused among persons who are mechanically ventilated. The use of remdesivir and dexamethasone varied across health systems, suggesting variation in patient case mix, drug access, treatment protocols, and quality of care.
引用
收藏
页码:1395 / +
页数:11
相关论文
共 50 条
  • [1] Use of hydroxychloroquine, remdesivir, and dexamethasone among adults hospitalized with COVID-19 in the United States: Results from the National COVID Cohort Collaborative (N3C)
    Mehta, Hemalkumar B.
    An, Huijun
    Andersen, Kathleen M.
    Mansour, Omar
    Madhira, Vithal
    Rashidi, Emaan S.
    Bates, Benjamin
    Setoguchi, Soko
    Joseph, Corey
    Kocis, Paul
    Moffitt, Richard
    Bennett, Tellen D.
    Chute, Christopher
    Garibaldi, Brian T.
    Alexander, G. Caleb
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 27 - 27
  • [2] THE EFFICACY OF REMDESIVIR WITH DEXAMETHASONE VS. DEXAMETHASONE ALONE IN ADULTS HOSPITALIZED WITH COVID-19: A RETROSPECTIVE COHORT STUDY
    Al-Mistarehi, Abdel-Hameed
    Ata, Ehab M. Bani
    Mashina, Marwan M. M.
    Alghzawi, Fadi
    Khassawneh, Ahmad B.
    Ibnian, Ali M.
    Alaabdin, Anas M. Zein
    Jadallah, Abdullah A.
    Alomari, Safwan
    Al Sbihi, Ali
    Kheirallah, Khalid A.
    Alzoubi, Abdallah
    Khassawneh, Basheer Y.
    CHEST, 2022, 162 (04) : 657A - 658A
  • [3] Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States
    Chokkalingam, Anand P.
    Hayden, Jennifer
    Goldman, Jason D.
    Li, Hu
    Asubonteng, Julius
    Mozaffari, Essy
    Bush, Christopher
    Wang, Jocelyn R.
    Kong, Amanda
    Osinusi, Anu O.
    Gottlieb, Robert L.
    JAMA NETWORK OPEN, 2022, 5 (12) : E2244505
  • [4] Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study
    Gressens, Simon B.
    Esnault, Violaine
    De Castro, Nathalie
    Sellier, Pierre
    Sene, Damien
    Chantelot, Louise
    Hervier, Baptiste
    Delaugerre, Constance
    Chevret, Sylvie
    Molina, Jean-Michel
    PLOS ONE, 2022, 17 (02):
  • [5] Hospital-level Variation in COVID-19 Treatment Among Hospitalized Adults in the United States: A Retrospective Cohort Study
    Mehta, Hemalkumar B.
    Garibaldi, Brian
    An, Huijun
    Andersen, Kathleen M.
    Robinson, Matthew
    Wang, Kunbo
    Xu, Yanxun
    Betz, Joshua
    Wu, Albert
    Fisher, Arielle
    Egloff, Shanna
    Sands, Kenneth E.
    Alexander, G. Caleb
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 193 - 193
  • [6] Clinical use of remdesivir in COVID-19 treatment: a retrospective cohort study
    Pham, Hong Tham
    Mai-Phan, Tuong-Anh
    Vu, Anh Kiet
    Truong, Thi Ha
    Tran, Minh-Hoang
    BMJ OPEN, 2023, 13 (06):
  • [7] Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
    Kaur, Amritpal
    Chaudhary, Gaurav
    Singh, Pargat
    Arora, Sandeep
    Kaur, Rajwinder
    CURRENT DRUG TARGETS, 2021, 22 (13) : 1536 - 1547
  • [8] Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study
    Yasuda, Yuto
    Hirayama, Yutaka
    Uemasu, Kiyoshi
    Arasawa, Soichi
    Iwashima, Daisuke
    Takahashi, Ken-Ichi
    RESPIRATORY MEDICINE AND RESEARCH, 2022, 81
  • [9] Dexamethasone, dexamethasone plus remdesivir in treating moderate to severe COVID-19: retrospective observational cohort study
    Sattoju, Nithish
    Gattu, Santosh
    Merugu, Sai Sashank
    Anneboina, Vydhika
    Ganapaka, Sai Ram
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2023, 17 (07): : 953 - 960
  • [10] A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
    Ngo, Dallis Q.
    Hamid, Kewan
    Rana, Haris
    Cardinale, Maria
    Frenia, Douglas
    Ghani, Nabil
    Redel, Henry
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2022, 2022